MGFB Biopharma

MGFB Biopharma is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapies for metabolic and fibrotic diseases. The company's lead program, MGFB01, is a highly selective thyroid hormone receptor beta (THRβ) agonist currently in Phase 2 clinical trials for the treatment of metabolic-associated steatohepatitis (MASH). MGFB Biopharma leverages its deep expertise in metabolic pathways to build a pipeline of small molecule candidates targeting high-unmet-need conditions such as dyslipidemia and obesity. Founded in 2020 by industry veterans with extensive experience at global pharmaceutical firms, the company maintains research and development operations in both Suzhou, China, and the United States. MGFB Biopharma is backed by prominent venture capital firms, including Qiming Venture Partners and TF Capital.